Women taking raloxifene seem less likely to develop invasive breast cancer that is oestrogen-receptor positive than women not taking it, according to data published in the Journal of the National Cancer Institute. The drug didn't lower the risk of non-invasive breast cancer or of oestrogen-receptor-negative breast cancer.
In a study testing raloxifene in women with, or at high risk of, heart disease, the drug didn't prevent heart disease, but it cut the risk of invasive oestrogen-receptor-positive breast cancer by 44%.
Raloxifene is a selective oestrogen receptor modulator (SERM). It is approved by the FDA to treat osteoporosis after the menopause and to reduce the risk of breast cancer, but not to treat or prevent heart disease.
0
Like
0
Love
0
Angry
0
Dislike
0
